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ABSTRACT
Aim: Little data is available on long-term renal impairment in
survivors from childhood sarcoma. We investigated the prevalence of
renal impairment and hypertension after very long-term follow-up
in survivors who reached adulthood after treatment for childhood
sarcoma. Methods: A cross-sectional single center study was per-
formed. Outcomes included estimating glomerular filtration rate
(eGFR), albuminuria, glycosuria, serum phosphate and magnesium,
tubular reabsorption phosphate (TRP), chronic kidney disease (CKD)
according to the “Kidney Disease: Improving Global Outcomes”
(KDIGO) guidelines and blood pressure (BP). Results: Out of 87> 5-
year sarcoma survivors, 30 adults (10F/20M, median age at diagnosis
9 years, median age at investigation 26 years, median follow-up 16
years, mean 19 years) were identified. Renal impairment was
detected in four cases (13.3%); three of these fulfilled the criteria for
CKD. Among the adult survivors, a subgroup of 15 cases (50%) had
received ifosfamide without confounding factors such as a diagnosis
of genito-urinary rhabdomyosarcoma or administration of other
potentially nephrotoxic chemotherapy (platinum-based drugs or
methotrexate); no renal dysfunction was detected in this subgroup.
In the whole cohort of sarcoma survivors, hypertension was diag-
nosed in four cases (13.3%); BP was significantly correlated with
body mass index [p .014]. Conclusion: In our series of adult survivors
treated for a diagnosis of sarcoma in their childhood, the prevalence
of CKD was 10%. We found survivors treated with ifosfamide as the
only nephrotoxic agent did not present glomerular or tubular tox-
icity at long term follow-up, but further studies including a larger
number of cases are required to confirm it.
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Introduction
The increased survival rate for children with cancer has led to the recognition of
chronic health conditions related to previous therapy in long term survivors.1–3 Late
treatment sequelae may be responsible for chronic diseases and reduced life expectancy
in survivors. Among the late effects of childhood cancer therapy are renal impairment
and associated hypertension. Occasionally, malignant disease itself may cause renal
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impairment by damaging normal renal tissue by tumor infiltration or by urinary tract
obstruction. More commonly, nephrotoxicity is a known side effect of certain childhood
cancer therapies, resulting in the decline of glomerular filtration rate (GFR), the
deterioration of tubular function, the development of albuminuria and hypertension.
Potentially nephrotoxic agents include ifosfamide, the platinum compounds cisplatin
and carboplatin, methotrexate, radiotherapy involving the kidney region.4–8 A recent
Cochrane systematic review on nephrotoxic childhood cancer treatments reported a
prevalence of long-term renal impairment ranging from 0 to 84%.9 This gap may be
due to multiple factors. Data is not homogenous respect to the malignancies, treat-
ments, outcomes measurements and time of follow-up. In particular, drug-renal adverse
effects are common during therapy or at short-term follow-up, but little data is available
on renal function impairment in adult survivors from childhood cancer and the evi-
dence about the long-term renal function impairment remains inconclusive. As more
and more patients reach adulthood, long-term effects of specific nephrotoxic agents
have become the focus of research to better define high-risk cases and to better design
effective surveillance strategies. Survivors with initial impaired renal function are usually
symptom free, but even in subjects with subclinical toxicity, the potential for serious
morbidity in later life is worrying. Chronic kidney disease (CKD) and hypertension are
two important and treatable cardiovascular risk factors. Survivors from soft tissue sar-
coma or from bone sarcoma may be at risk for nephrotoxicity because they are usually
treated by one or more potentially nephrotoxic drugs or because the disease involves
the genitourinary system.
In this study, we have invited the adult survivors of childhood sarcoma treated in a
single centre to receive a specific screening with the aim to evaluate the prevalence of
long term renal impairment and hypertension. To better evaluate the ifosfamide-related
nephrotoxicity, we selected among these survivors those who received ifosfamide
without confounding factors such as a diagnosis of genito-urinary rhabdomyosarcoma
(RMS) or chemotherapy with platinum-based drugs or methotrexate.
Patients and methods
After institutional authorization a cross-sectional single-center study was performed.
Demographic and clinical data were collected from the medical files of patients treated
for sarcoma at the Pediatric Oncology Unit of “Sapienza” University of Rome. Eligibility
criteria for the current study were as follows: diagnosis and treatment for sarcoma
since 1980; age 21 years at diagnosis; age at study 17 years, survival >5 years after
diagnosis, no high-dose chemotherapy with stem cell rescue, no kidney radiotherapy or
nephrectomy, no secondary tumor development. Follow-up time was defined as time
since cessation of treatment until renal function measurement. All eligible survivors
were invited to the outpatient clinic to receive specific screening. Informed consent was
obtained, as appropriate. Survivors underwent a physical examination, chemistry, kidney
ultrasound, urine analysis, and blood pressure (BP) measurement. They were matched
for body mass index (BMI) because of the potential influence of body composition on
renal function and BP.
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Nephrotoxic agents were defined as follows: administration of ifosfamide, platinum-
based drugs (cisplatin or carboplatin) or methotrexate and a diagnosis of genito-urinary
RMS. To better evaluate the ifosfamide-related nephrotoxicity, we selected adult
sarcoma survivors in two groups, those who received ifosfamide as the only nephrotoxic
agent (group 1), and those who received multiple nephrotoxic agents (group 2).
Chemistry
For renal function evaluation, chemistry has included the determination of serum elec-
trolytes, Ca, Mg, P, BUN/creatinine and the determination of urine protein, creatinine,
glucose, and phosphate. Serum triglycerides >1.7mmol/L, high density lipoprotein chol-
esterol <1.03mmol/L for men, and <1.29mmol/L for women, and glucose >7mmol/L
were considered for diagnosis of diabetes and/or metabolic disease.
Renal function
Outcome measurements has included estimating (e)GFR, albuminuria, serum phos-
phate/hypophosphatemia, serum magnesium/hypomagnesaemia, tubular reabsorption
phosphate (TRP), kidney ultrasound and BP.
eGFR was calculated from serum creatinine standardized to isotope dilution mass
spectrometry (IDMS), in a single laboratory to avoid interlaboratory error in creatinine
determinations.10 Estimated glomerular function was calculated by the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation.11 We defined decreased GFR
as an estimated GFR <90mL/min/1.73 m2 and decline in GFR category (90 [G1],
60–89 [G2], 45–59 [G3a], 30–44 [G3b], 15–29 [G4], <15 [G5] mL/min/1.73m2), as
recommended by “Kidney Disease: Improving Global Outcomes” (KDIGO) guidelines.12
Albuminuria was evaluated using a 24-h urine collection for albumin excretion; albu-
min urine concentrations were assessed using the immunological method. Albuminuria
was expressed according to A1-3 categories by KDIGO guidelines.12 A threshold for
urinary albumin excretion of 30mg/24 h sustained for >3 months was considered
pathological.
Tubular function was assessed by measuring serum phosphate, magnesium, and other
electrolytes, by measuring glycosuria, urine PH, and by the determination of tubular
reabsorption phosphate (TRP). Serum phosphate, magnesium, and other electrolytes
were considered normal if the value was in the normal range and replacement therapy
was not being administered. TRP was calculated by the following formula:
ð1 Cr S x P UCr U x P S Þ 100 (Cr, creatinine; P, phosphate; S, serum; U, urinary), it was
considered in normal value 80%.
Kidney ultrasound was assessed for signs of kidney damage (nephrocalcinosis, cysts,
hydronephrosis, stones, and scars).
Persistent eGFR <60mL/min/1.73m2 or albuminuria or tubular dysfunction or
abnormalities in kidney structure were considered as CKD. An eGFR <90> 60mL/min/
1.73m2 (G2 category) without other markers of kidney damage was not considered
CKD.12 The subjects that presented with CKD at the initial risk assignment were
reassessed after 3 or 6 months.
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Blood pressure
BP was measured in every case by the auscultatory method using a standard sphygmo-
manometer and a stethoscope and it was defined as hypertensive if systolic BP was
140mmHg, diastolic BP was 90mmHg, or any antihypertensive medication was
used. BP was measured three times and the lowest BP determination was recorded.
Pre-hypertension was not recorded. Possible correlation was investigated between BMI
and systolic BP.
Statistical analysis
The comparison between frequency of eGFR <90mL/min/1.73m2, of TRP, and of CKD
was analyzed using two tails Fisher’s Exact Test. Correlation between systolic BP and
BMI was performed using Spearman’s Test Rho. The results were considered statistically
significant if the p value was<.05. Time (year) referred to patient age and follow-up
were rounded up and down.
Results
Sarcoma survivors
Out of 87 five-year survivors, 42 were adults who presented with the inclusions criteria
for the study. Twelve of these were lost or refused to participate, thus 30 cases were
investigated; their characteristics are shown in the Table 1. Ten were females and 20
males, the median age at diagnosis was 9 years (range 0.8–21), mean 9 years, SD 6.27.
Twenty-one had been treated for RMS, 2 for soft tissue sarcoma, 4 for Ewing sarcoma
(ES), and 3 for osteosarcoma. The median follow-up was 16 years (range 6–34), mean
19 years, SD 7.79. The median age at investigation was 26 years (range 17–47 years),
mean 28 years, SD 8.58. Patients lost to follow-up were similar to those evaluated in
terms of sex (5F, 7M), median age at treatment (10 years), malignancy (10 RMS, 1 ES,
2 soft tissue sarcoma). No patient received high-dose chemotherapy with stem cell
rescue or whole abdomen radiotherapy or radiotherapy on kidney field. Twenty-four
cases had received local radiotherapy, three of these on bladder site. Among 30 adult
sarcoma survivors, 11 had BMI 25 and another one had BMI 36. Two of these cases
fulfilled the criteria for metabolic disease.
Group 1 consisted of 15 out of 30 adult sarcoma survivors (50%). Group 1 (5 females
and 10 males) had a median age at diagnosis of 13 years (range 2–21), a median age at
investigation of 28 years (range 17–47), and a median follow-up of 17 years (range
7–28). Median ifosfamide cumulative dose was 54 g/m2 (range 18–106), mean 60.9 g/m2,
SD 24.7; ifosfamide was associated with vincristine, actinomycin D or doxorubicin
or etoposide.
Group 2 sarcoma survivors (5 females and 10 males) had a median age at diagnosis
of 6 years (range 0.8–17), a median age of investigation of 23 years (range 17–46), and a
median follow-up of 16 years (range 6–34). They received multiple nephrotoxic agents:
ifosfamide (median cumulative dose of 48 g/m2), other nephrotoxic drugs or surgery/
radiotherapy for bladder RMS.
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Renal function
The mean eGFR in all cohort of survivors was 110.6mL/min/1.73mq (103.6–118.0
95% C.I.).
Renal impairment was detected in four cases (13.3%) Table 1.
Case n 1: eGFR <60mL/min/1.73m2, albuminuria A2 category, TRP 49%, hypophos-
phatemia, urine PH >7.
Case n 2: eGFR <90mL/min/1.73m2 and TRP 76%.
Case n 3: albuminuria A2 category
Case n 4: eGFR <90mL/min/1.73m2
Cases n 1, 2, 3 fulfilled the criteria for CKD according to KDIGO guidelines. They
were referred to a nephrology unit. Two of these (n1 and n3) had received surgery
(cystectomy/partial cystectomy) and radiotherapy for bladder RMS. In particular, case
n 1 with CKD at stage 3a is continuing screening and replacement therapy in a
nephrology center.
Serum magnesium, calcium and electrolytes were in the normal range with no
replacement therapy in the remaining 29 cases.
Table 1. Characteristics and renal function in sarcoma survivors.
Variables Survivors (n30)
Age at diagnosis (yrs)
median (range) 9 (0.8–21)
Age at study (yrs)
median (range) 26 (17–47)
Follow-up (yrs)
median (range) 16 (6–34)
Nephrotoxic chemotherapy
n (frequency)
Only Ifo 17 (57%)
Carbo 7 (23%)
Mtx 3 (10%)
Cis 3 (10%)
Radiotherapy
n (frequency)
Kidney region 0
Bladder 3 (10%)
Other sites 21 (70%)
Not 6 (20%)
Albuminuria 30mg/24 h
n (frequency) 2 (6.6%)
eGFR mL/min/1.73 m2
n (frequency)
<90 2 (6.6%)
<60 1 (3.3%)
TRP <80%
n (frequency) 2 (6.6%)
Glicosuria
n 0
hypoMg
n (frequency) 0
hypoP
n (frequency) 1 (3.3%)
CKD
n (frequency) 3 (10%)
Note. N: number; yrs: years; ifo: ifosfamide; carbo: carboplatin; mtx: methotrexate; cis:
cisplatin; eGFR: estimated glomerular filtration rate; TRP: tubular reabsorption of phosphate;
hypoMg: hypomagnesemia; hypoP: hypophosphatemia; CKD: chronic kidney disease.
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Group 1 sarcoma survivors presented with a mean eGFR of 115mL/min/1.73m2 and
had no G2 or G3 category or tubular dysfunction or CKD (Table 2). Group 1 sarcoma
survivors had a better renal function in comparison with group 2 sarcoma survivors
(Table 3).
Hypertension
Four (13.3%) out of 30 sarcoma survivors had hypertension. Systolic BP was signifi-
cantly correlated with BMI (p .014; Figure 1).
Discussion
In this study, we investigated the long term renal function assessed by KDIGO criteria
in adult survivors of childhood sarcoma after a median follow-up of 16 years, (mean 19
years; range 6–34 years). The prevalence of renal impairment was 13.3%. Three (10%)
Table 3. Renal function in group 1 sarcoma survivors (ifosfamide without other
nephrotoxic agents) and group 2 sarcoma survivors.
Variables
Group 1
n15
Group 2
n15 p Value
Mean eGFR 114.5 ± 15.9 105.73 ± 22.6 n.s.
eGFR <90
n 0 3 p¼ .05
CKD
n 0 3 p¼ .05
TRP <80%
n 0 2 n.s.
HypoP
n 0 1 n.s.
Note. n: number; IFO: ifosfamide; eGFR: estimated glomerular filtration rate; CKD: chronic
kidney disease; TRP: tubular reabsorption phosphate; HypoP: hypophosphatemia.
Table 2. Characteristics of survivors treated with ifosfamide without cisplatin, carboplatin, methotrexate and without
diagnosis of bladder rhabdomyosarcoma.
Pt H
AgeD
yrs
AgeS
yrs
FU
yrs
Total dose IFO
g/m2
A
mg/24 h eGFR TRP Mg P CKD
1 RMS 2 18 15 54 12.9 135 86% 1.9 3.7 no
2 ES 17 28 11 106 2.2 118 97% 2.2 3.4 no
3 ES 14 33 19 27 4.1 122 86% 2.1 2.8 no
4 RMS 13 21 7 54 2 107 91% 2.1 4.3 no
5 RMS 21 47 24 54 2.9 112 81% 1.9 3.4 no
6 RMS 17 39 22 18 6.7 96 80% 2.3 2.8 no
7 RMS 20 28 9 54 2.4 102 88% 2.1 3.4 no
8 RMS 6 25 18 54 3.4 93 92% 2 4 no
9 RMS 9 29 18 54 9 115 81% 2 3.4 no
10 RMS 16 33 17 90 1 92 92% 2.1 3.7 no
11 RMS 6 33 27 54 1.3 99 86% 2 4 no
12 ES 17 28 11 102 12 129 90% 2 3.4 no
13 RMS 5 17 11 54 10 140 92% 2.2 4.6 no
14 RMS 2 29 28 84 3.4 133 90% 1.8 3.7 no
15 RMS 9 24 15 54 4.6 133 94% 2.1 3.7 no
Note. Pt: patient; H: histology; yrs: years; FU: follow-up; IFO: ifosfamide; A: albuminuria; eGFR: estimated glomerular
filtration rate; TRP: tubular reabsorption phosphate; Mg: magnesium; P: phosphate; RMS: rhabdomyosarcoma; ES:
Ewing sarcoma; ARMS: alveolar rhabdomyosarcoma; ERMS: embryonal rhabdomyosarcoma; BRMS: botryoides rhabdo-
myosarcoma; D: diagnosis; S: study.
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survivors fulfilled the criteria for CKD, but two of them had received surgery
(cystectomy/partial cystectomy) and radiotherapy for bladder rhabdomyosarcoma.
Actually, 40% of bladder/prostate rhabdomyosarcoma survivors had decreased renal
function, thus we considered this site of disease as a potentially nephrotoxic agent other
than ifosfamide.13 In our cohort, ifosfamide-treated survivors without other potentially
nephrotoxic agents association did not present with renal dysfunction.
The majority of patients affected by childhood sarcoma receive one or more
potentially nephrotoxic drugs for cancer treatment. Since the 1980s, ifosfamide was
introduced in most of the treatment protocols for childhood soft tissue and bone
sarcomas. Ifosfamide may cause glomerular and tubular damage during or after admin-
istration, but there are few studies that have examined the long-term nephrotoxicity. To
examine the long term renal toxicity of ifosfamide, we selected in our cohort of adult
sarcoma all cases who had received ifosfamide but no platinum-based drugs (cisplatin
or carboplatin) or methotrexate and do not have a diagnosis of genito-urinary rhabdo-
myosarcoma. No tubular dysfunction, no CKD and no eGFR <90mL/min/1.73m2 have
been detected in this population. This data is not consistent with most data that has
been reported in the literature, so far. However, most published studies have reported
data on ifosfamide nephrotoxicity after a short term follow-up. Skinner et al conducted
a multi-center cross-sectional study evaluating the effects of ifosfamide treatment in 148
cancer survivors at a median time of follow-up of 6 months following the completion of
chemotherapy; they found that 50% of the sample population had GFR <90mL/min/
1.73m2, 9% <60mL/min/1.73m2, and 21% had hypophosphatemia.14 Although the
sample size was larger than that in the present study, the follow-up was very short.
Rossi et al investigated renal function in 75 patients at a median of follow-up of
31months, they reported a Fanconi syndrome in 7% of the cases and a subclinical
tubular toxicity in 9% of the cases.15 Loebstein et al screened 174 patients affected by
different tumors who had received ifosfamide, that was associated with cisplatin in 70%
Figure 1. Systolic blood pressure as function of body mass index in sarcoma survivors. BMI: body
mass index; SBP: systolic blood pressure.
PEDIATRIC HEMATOLOGY AND ONCOLOGY 173
of the cases; they found renal tubular toxicity in 41.4% of the cases and glomerular tox-
icity in 6.3% of the cases, at short term follow-up.16 Stohr et al reported a lower grade
of nephrotoxicity. The authors screened 593 patients treated for sarcomas at median
follow-up of 19 months and reported a tubular toxicity only in 4.6% of the cases.17
There are two published very long-term follow up studies, that had investigated ifosfa-
mide nephrotoxicity at a longer follow-up.18,19 Oberlin et al studied 183 patients after a
median follow-up of 10 years.18 The authors found a GFR <90mL/min/1.73m2 in 21%
of the cases, a GFR <60mL/min/1.73m2 in 0.5% and a tubular dysfunction in 10.5%.
They concluded that despite late common tubular toxicity after ifosfamide treatment,
this risk is mild and when present, toxicity is moderate when the cumulative ifosfamide
dose is low (91% of the patients had received 60 g/m2 or less).18 In this study, it was
not specified if bladder/prostate RMS survivors were included among the analyzed cases.
Oberlin et al also found that the length of follow-up between the end of ifosfamide
treatment and investigations was linked with a risk of proximal tubular damage. This
feature does not correlate with other studies which described a possible improvement of
renal function with time in some children.19,20 Skinner et al reported a longitudinal
study on 25 patients diagnosed with sarcomas, who were treated with a median cumula-
tive ifosfamide dose of 104 g/m2.19 They suggested that tubular toxicity improves over a
period of several years, although similar recovery does not appear to occur in glomeru-
lar function. Indeed, they found that clinically significant tubular toxicity had resolved
by 10 years whereas GFR <60mL/min/1.73 m2 was found in 13% of patients. However,
8% of these cases underwent high dose chemotherapy or total body irradiation.19 In the
present study, we were not able to detect an eventual improvement of renal function in
our cases, because we did not perform a longitudinal study with the same outcomes. At
cross-sectional study, survivors treated with ifosfamide as the only nephrotoxic agent
did not present glomerular or tubular toxicity at long-term follow-up. A major limita-
tion of this study was that it was a single institution study with a small number of cases,
nevertheless the survivors have received an exhaustive renal function assessment at
long-term follow-up.
Hypertension is another important outcome related to renal function. In our study,
the prevalence of hypertension was 13.3% in adult sarcoma survivors. It was higher
than that we found in the cohort of adult survivors from unilateral non-syndromic renal
tumor,21 although this difference was not statistically significant. The possible cause
could be related to the higher prevalence of overweight/obesity among adult survivors
of sarcoma than that among uninephrectomized cases.20 Overweight and obesity are
known risk factors for hypertension in the general population. We found a statistically
significant correlation between systolic BP and BMI in sarcoma survivors.
Cardoos-Ubbink et al also demonstrated that BMI is the most important risk factor
for hypertension following treatment of childhood cancer, emphasizing the need for
cancer survivors to maintain a normal weight, although a recent study on a large
number of survivors found that BP was substantially higher in all diagnosis groups than
expected on the basis of age-, sex-, race/ethnicity-, and BMI-specific population
rates.22,23
In conclusion, in the present study long-term sarcoma survivors previously treated
with ifosfamide as the only nephrotoxic agent do not seem to be at high risk for
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nephrotoxicity. This finding has not been reported so far, it could be conditioned
by the small number of cases, and further studies including a larger number of adult
long-term survivors are required.
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